Ketamine-Induced Urologic Insult (KIUI)-E343-E346

Pain Physician

Volumn 13, Issue 6, 2010, Pages

  Smith, Howard S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HYALURONIC ACID; INTERLEUKIN 6; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ALLODYNIA; ARTICLE; BLADDER BIOPSY; CHRONIC DRUG ADMINISTRATION; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROME; CREATININE BLOOD LEVEL; CYSTITIS; CYSTOSCOPY; DELAYED DIAGNOSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG MECHANISM; DRUG WITHDRAWAL; DYSURIA; ENANTIOMER; GENE EXPRESSION; HEMATURIA; HUMAN; HYDRONEPHROSIS; KIDNEY DISEASE; LEG PAIN; LOW BACK PAIN; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; OVERACTIVE BLADDER; PATIENT CARE; PRESCRIPTION; QUANTITATIVE ANALYSIS; SIDE EFFECT; URINARY FREQUENCY; URINARY URGENCY; URODYNAMICS;

ANALGESICS; CYSTITIS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; URINARY BLADDER;

EID: 78649550029     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Legge J, Ball N, Elliott DP. The potential role of ketamine in hospice analgesia a literature review. Consult Pharm 2006; 21:51-57.
2. Lester L, Braude DA, Niles C, Crandall CS. Low-dose ketamine for analgesia in the ED: a retrospective case series. Am J Energ Med 2010; 28:820-827.
3. Chazan S, Ekstein MP, Marouani N, Weinbroum AA. Ketamine for acute and subacute pain in opioid-tolerate patients. J Opioid Manage 2008; 4:173-180.
4. Bell R, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2003;(1):CD003351.
5. Angst MS, Clark JD. Ketamine for managing perioperative pain I opioid-dependent patients with chronic pain: a unique indication? Anesthesiology 2010; 113:514-515.
6. Mercadante S, Lodi F, Sapio M, Calligara M, Serretta R. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage 1995; 10:545-568.
7. Mercadante S, Villari P, Ferrera P, Arcuri E, David F. Opioid switching and burst ketamine to improve the opioid response in patients with movementrelated pain due to bone metastases. Clin J Pain 2009; 25:648-649.
8. Mercadante S, Arcuri E, Tirellu W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000; 20:246-252.
9. Mercadante S, Villari P, Ferrera P. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage 2003; 25:302-305.
10. Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 2005; 30:485-491.
11. Mercadante S. Ketamine in cancer pain: an update. Palliat Med 1996; 10:225-230.
12. Bell RF. Ketamine for chronic non-cancer pain. Pain 2009; 141:210-214.
13. Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A. Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother 2010; 11:2417-2429.
14. Elsewaisy O, Sion B, Monagle J. Analgesic effect of subanesthetic intravenous ketamine in refractory neuropathic pain: a case report. Pain Med 2010; 11:946-950.
15. Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a doubleblind placebo controlled study. Pain 2009; 147:107-115.
16. Sigtermans MJ, van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY, Dahan A. Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009; 145:304-311.
17. Goldberg ME, Torjman MC, Schwartzman RJ, Mager DE, Wainer IW. Pharmacodynamic profiles of ketamine (R)-and (S)-with 5-day inpatient infusion for the treatment of complex regional pain syndrome. Pain Physician 2010; 13:379-387.
18. Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine. Pain 2009; 146:18-25.
19. Chizh BA. Low dose ketamine: a therapeutic and research tool to explore Nmethyl-D-aspartate (NMDA) receptormediated plasticity in pain pathways. J Psychopharmacol 2007; 21:259-271.
20. Lois F, De Kock M. Something new about ketamine for pediatric anesthesia? Curr Opin Anaesthesiol 2008; 21:340-344.
21. Wu GJ, Chen TL, Ueng YF, et al. Ketamine inhibits tumor necrosis factor-alpha and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of tolllike receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activation. Toxicol Appl Pharmacol 2008; 228:105-113.
22. De Kock MF, Lavand'homme PM. The clinical role of NMDA receptor antagonists for the treatment of postoperative pain. Best Pract Res Clin Anaesthesiol 2007; 21:85-98.
23. Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol 2008; 182:313-333.
24. Persson J, Hasselstrom J, Maurset A, et al. Pharmacokinetics and nonanalgesic effects of S-and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol 2002; 57:869-875.
25. Chu PS, Ma WK, Wong SC, Chu RW, Cheng CH, Wong S, Tse JM, Lau FL, Yiu MK, Man CW. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 2008; 102:1616-1622.
26. Colebinders B, Van Erps P. Cystitis due to the of ketamine as a recreational drug: a case report. J Med Case Reports 2008; 2:219.
27. Oxley JD, Cotrell AM, Adams A, Gillatt D. Ketamine cystitis as a mimic of carcinoma in situ. Histopathology 2009; 55:705-708.
28. Cottrell AM, Ayres R, Weinstock P, Warren K, Gillatt D. Urinary tract disease associated with chronic ketamine use. MBJ 2008; 338:973.
29. Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 2007; 69:810-12.
30. McCambridge J, Winstock A, Hunt N, Mitcheson L. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res 2007; 13:57-64.
31. Chen KT, Foo NP, Lin HJ. Frequent visits with urinary symptoms: subtle signs of ketamine abuse. Am J Emerg Me. 2008; 26:1061-1062.
32. Dhillon, BS, Nuttall, MC, Coull, N, O'Brien, TS. Minerva. BMJ 2008; 336:898.
33. Storr TM, Quibell R. Can ketamine prescribed for pain cause damage to the urinary tract? Palliat Med 2009; 23:670-672.
34. Muetzelfeldt, L, Kamboja, SK, Ressa, H, Taylora, J, Morgana, CJA, Currana, HV. Journey through the K-hole: Phenomenological aspects of ketamine use. Drug Alcohol Depend 2008; 95:219-229.
35. Tsai TH, Cha TL, Lin CM, Tsao CW, Tang SH, Chuang FP, Wu ST, Sun GH, Yu DS, Chang SY. Ketamine-associated bladder dysfunction. Int J Urol 2009; 16:826-829.
36. Castroman PJ, Ness TJ. Ketamine, an Nmethyl-d-aspartate Receptor Antagonist, Inhibits the Spinal Neuronal Responses to Distension of the Rat Urinary Bladder. Anesthesiology 2002; 96:1410-1419.
37. Mason K, Cottrell A, Corrigan AG, Gillatt DA, Mitchelmore AE. Ketamine-associated lower urinary tract destruction: a new radiological challenge. Clin Radiol 2010; 65:795-800.
38. Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pflüger H. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19: 717-721.
39. Kirkpatrick AF. Regarding Bell and Moore, Intravenous ketamine for CRPS: Making too much of too little? Pain 2010; In Press.
40. Persson J. Wherefore ketamine? Curr Opin Anaesthesiol 2010; 23:455-460.